The Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) is an investigator-initiated study conducted ...

Aimed at patients who are ineligible to take part in other clinical trials due to their advanced stage ALS, the trial hopes ...

A newly awarded grant from the ALS Association will support Asha Therapeutics' work to advance ASHA-624 into a first-in-human ...

Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for ...

Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...

Neurizon Therapeutics Limited , a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is ...

Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Verge Genomics and Eli Lilly (NYSE: LLY) have announced significant progress in their joint efforts to develop novel ...

amyotrophic lateral sclerosis (ALS). The latter condition – also known as Lou Gehrig’s disease – causes damage to the nerve ...